相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1848
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Youth with type 1 diabetes who started automated insulin delivery within 6 months of diagnosis achieved a median HbA1c of 7.1% at 2 years, significantly better than non-users at 8%. - Early automated insulin delivery users were 82% more likely to achieve HbA1c below 7% at 2 years compared to those not using the technology. - Real-world data from 9,856 children showed progressively better outcomes with earlier system initiation, including reduced diabetic ketoacidosis rates. - The findings suggest automated insulin delivery may help prevent the typical post-honeymoon HbA1c rise that occurs after initial type 1 diabetes diagnosis.
- MiNK Therapeutics announced the initiation of a Phase 1 clinical trial evaluating agenT-797, an off-the-shelf allogeneic iNKT cell therapy, in patients undergoing stem cell transplantation to prevent graft-versus-host disease. - The investigator-sponsored trial will assess safety, tolerability, and preliminary efficacy of agenT-797 in reducing GvHD, relapse, and post-transplant complications in patients with high-risk leukemias and blood cancers. - The therapy represents a novel approach that requires no lymphodepletion or HLA matching, potentially offering improved outcomes for transplant patients while addressing a complication affecting up to half of stem cell transplant recipients. - The study is supported by complementary funding from an NIH STTR grant and the Mary Gooze Clinical Trial Award, enabling simultaneous translational and clinical research.
- Archeus Technologies has dosed the first patient in a Phase 1 clinical trial of ART-101, a novel PSMA-targeting radioligand therapy for metastatic castration-resistant prostate cancer. - Preclinical studies demonstrated that ART-101 exhibits higher tumor uptake and retention while showing lower normal tissue and salivary gland uptake compared to current FDA-approved PSMA-targeting agents. - The Phase 1 study will enroll approximately 10 mCRPC patients to evaluate safety, biodistribution, and tumor targeting using SPECT/CT imaging with [111In]In-ART-101. - The therapy was developed at the University of Wisconsin-Madison and aims to address key limitations of existing radiopharmaceutical therapies, particularly reducing side effects like xerostomia.
- MiNK Therapeutics has been awarded a grant from the National Institute of Allergy and Infectious Diseases (NIAID) to advance its allogeneic iNKT cell therapy platform for preventing graft-versus-host disease following stem cell transplantation. - The collaboration with the University of Wisconsin aims to address the needs of nearly 50% of patients undergoing allogeneic stem cell transplants who are at risk for this serious and potentially life-threatening complication. - iNKT cells offer unique advantages in this setting due to their natural ability to regulate immune responses, promote tissue repair, and suppress inflammatory pathways while preserving infection-fighting capabilities. - The company's lead asset AGENT-797 is currently in clinical development for treating graft-versus-host disease, solid tumors, and critical pulmonary immune collapse.
- Children participating in team sports like soccer and volleyball demonstrate superior executive function skills compared to those in individual sports or no sports, according to a Dutch longitudinal study published in JAMA Network Open. - Structured sports participation increases high school graduation rates, with boys showing a 15% higher likelihood and girls a 7% higher likelihood of obtaining diplomas by age 20, research from the University of Montreal reveals. - Girls engaged in organized and artistic sports achieved 8% and 23% higher grades respectively, highlighting the significant cognitive and academic benefits of team-based physical activities.
- The MANDARA study extension demonstrates that benralizumab maintains remission in 62.1% of EGPA patients through 104 weeks, with 43.9% achieving complete oral glucocorticosteroid withdrawal. - Benralizumab's superior eosinophil depletion mechanism, targeting IL-5 receptors rather than IL-5 directly, provides more complete and rapid eosinophil suppression compared to mepolizumab. - Real-world evidence confirms that IL-5 pathway inhibitors significantly reduce disease burden, with mepolizumab showing 18% reduction in daily oral corticosteroid use and 49% decrease in EGPA-related hospitalizations. - The convenience advantage of benralizumab's monthly dosing versus mepolizumab's requirement for three monthly injections may improve patient compliance and treatment outcomes.
